BMS’ Abilify Label Adds More Bipolars
This article was originally published in The Pink Sheet Daily
Executive Summary
Maintenance in pediatrics, teens made official by FDA.
You may also be interested in...
Antipsychotic Not Certain Savior For Forest
Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.
Antipsychotic Not Certain Savior For Forest
Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.
Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.